Hemodynamic Effects of a Novel Myeloperoxidase Inhibitor With Exercise in Heart Failure With Preserved Ejection Fraction - A Randomized, Double-Blind, Placebo Controlled Proof of Principle Study
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Mitiperstat (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- 17 May 2022 Status changed from recruiting to completed.
- 07 Mar 2022 Planned number of patients changed from 30 to 36.
- 02 Jun 2021 Planned End Date changed from 21 Apr 2021 to 21 Apr 2022.